Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study
Scott D. Lee
, David T. Rubin
, William J. Sandborn
, Charles Randall
, Ziad Younes
, Stefan Schreiber
, David A. Schwartz
, Robert Burakoff
, David Binion
, Themos Dassopoulos
, Razvan Arsenescu
, Alexandra Gutierrez
, Ellen Scherl
, Cem Kayhan
, Iram Hasan
, Gordana Kosutic
, Marshall Spearman
, David Sen
, Jason Coarse
, Stephen Hanauer
Division of Gastroenterology
Institute of Clinical and Translational Sciences (ICTS)
Research output
:
Contribution to journal
›
Article
›
peer-review
6
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Crohn's Disease
100%
Disease Exacerbation
100%
Re-induction
100%
Certolizumab Pegol
100%
Adverse Events
28%
Tumor Necrosis Factor Antagonist
14%
Placebo
14%
Remission Rate
14%
Malignancy
14%
Incidence Rate
14%
Serious Infection
14%
Lack of Response
14%
Disease Duration
14%
Limited Treatment Options
14%
Clinical Remission
14%
Open-label Extension
14%
Placebo-controlled Study
14%
Loss of Response
14%
Safety Signal
14%
Therapy Discontinuation
14%
Secondary Failure
14%
Primary Failure
14%
Pharmacology, Toxicology and Pharmaceutical Science
Disease Exacerbation
100%
Crohn's Disease
100%
Certolizumab Pegol
100%
Adverse Event
28%
Remission
28%
Tumor Necrosis Factor
14%
Infection
14%
Placebo
14%
Disease Duration
14%
Placebo-Controlled Study
14%